Testosterone pellets: steady levels, and no way to take them back

The flattest testosterone curve available, bought with the one property no other route has: once the pellets are in, the dose is fixed until they dissolve. Everything worth knowing about this route follows from that single fact.

How the release works

Established clinical use Pellets are small crystalline cylinders of testosterone, typically 75 mg each, placed in subcutaneous fat through a trocar under local anaesthetic, usually in the upper outer buttock. They have no ester and no carrier oil: release is governed by surface dissolution of the crystal itself, which is why the curve is so flat and why it stretches over months rather than days.

That also means there is no half-life to model in the usual sense, which is why the fact box above carries no pharmacokinetic rows — the app holds none for this entry. The release profile is a slow decline over three to six months rather than a repeating peak and trough, and the level people describe as a trough is the tail end before the next insertion.

The flatness is the genuine advantage. Someone whose symptoms track the injection cycle — good for four days, flat for three — is describing a problem this route does not have. Adherence is the other: two or three appointments a year replaces a weekly task.

The irreversibility is the whole risk

Every other testosterone route can be stopped. A gel is washed off, an injection is not repeated, a tablet is not taken. A pellet keeps releasing for months regardless of what anyone learns in the meantime. Off-label or community practice If the amount turns out to be too high — haematocrit climbing, estradiol symptomatic, mood worsening — the options are to manage around it or to have the pellets surgically removed, and removal is not always straightforward once they have partly dissolved.

That is why the first insertion is the one that deserves the most conservatism, and why people already established on injections have more information to size it with than someone starting from scratch. It is also why the app puts haematocrit at four weeks post-insertion on the monitoring list rather than at the usual interval: the point is to catch a problem while there is still time to plan around it.

Extrusion — a pellet working its way back out through the insertion site — happens in a small percentage of procedures, and site infection is uncommon but real. Both are procedural risks that the other routes do not have at all, and both are reasons the insertion site is on the monitoring list.

Approved product, and the compounded parallel

Established clinical use There is an FDA-approved pellet product, which is unusual in this reference and means a real manufacturing standard and a real label. There is also a large parallel market in compounded pellets used in hormone-therapy practices, and those are not the same thing: a compounded pellet has not been through the approval process, its dose consistency depends on the compounder, and pellets in particular are a formulation where crystal size and packing affect the release rate.

That distinction is worth asking about directly, because both are described with the same word. This site names no clinic and no pharmacy.

Monitoring is drawn at two points for a reason: about four weeks after insertion, near the peak of the release, and again just before the next insertion, at the trough. Two numbers three months apart describe the curve; one number does not tell you which part of it you measured. Everything about whether this route suits a particular person is a prescribing conversation, and it is one to have before the first insertion rather than after.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Testosterone Pellets, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• Free versus total testosterone, and the three ways labs get the free number
• Hematocrit on testosterone therapy

Drawbacks and risks the app records

From the app’s own entry, and the first and last items are the same problem stated twice — which is a fair reflection of how much it dominates this route.

• Dosing cannot be adjusted once implanted — must wait for dissolution
• Minor surgical procedure — trocar insertion under local anesthesia
• Risk of extrusion (pellet works out) — 1-5%
• Infection risk at insertion site (low but real)
• More expensive than injectable TRT per dose
• No ability to stop therapy immediately if side effects emerge

Questions people actually ask

Can pellets be removed if something goes wrong?

Surgically, yes, and it is not always simple once they have begun dissolving. That is the reason to be conservative on a first insertion rather than to plan on correction.

When should bloodwork be drawn?

Two points: about four weeks after insertion, near the top of the release, and just before the next one, at the bottom. The app’s own panel says the same. A single mid-interval draw does not tell you which part of the curve it came from.

Are compounded pellets the same as the approved product?

No. One has been through approval with a manufacturing standard behind it; the other depends on the compounder. For a formulation where crystal packing affects release rate, that is not a technicality — and both are called pellets.

Why is there no half-life in the fact box?

Because the app holds none, and the release mechanism is surface dissolution rather than clearance of a depot. The profile is a months-long decline, not a repeating curve, so a half-life would not describe it.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.